Drug Tolerance: A Known Unknown in Translational Neuroscience
| Autor: | Thomas J. Hudzik, Reinhold Müller, Anton Bespalov, Ana-Lucia Relo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug media_common.quotation_subject Drug Evaluation Preclinical Toxicology Bioinformatics Neuropsychiatry Translational Research Biomedical 03 medical and health sciences 0302 clinical medicine Drug tolerance Drug Discovery medicine Animals Humans media_common Pharmacology Psychotropic Drugs Drug discovery business.industry Neurosciences Drug administration Drug Tolerance medicine.disease 030104 developmental biology Drug development Schizophrenia business 030217 neurology & neurosurgery Translational neuroscience |
| Zdroj: | Trends in Pharmacological Sciences. 37:364-378 |
| ISSN: | 0165-6147 |
| Popis: | In neuropsychiatric drug development, the rate of successful translation of preclinical to clinical efficacy has been disappointingly low. Tolerance, defined as a loss of efficacy with repeated drug exposure, is rarely addressed as a potential source of clinical failures. In this review, we argue that preclinical methods of tolerance development may have predictive validity and, therefore, inclusion of studies using repeated drug exposure early during the drug discovery and development process should serve to mitigate a proportion of clinical failures. Our analysis indicates that many published preclinical efficacy studies in the neuropsychiatry arena are conducted with acute drug administration only. Furthermore, specifically in the field of schizophrenia, there are several examples where tolerance development may be suspected as a factor contributing to translational failures. These and other examples highlight the need for built-for-purpose tolerance studies to be conducted, regardless of the target interaction mode of the drugs (i.e., agonist or antagonist, allosteric or orthosteric). We suggest that, for compounds that have failed in clinical studies, preclinical efficacy data sets need to be revisited to estimate the potential impact of tolerance development, one of the most significant known unknowns in the preclinical-to-clinical translation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect